For men fighting metastatic hormone-sensitive prostate cancer (mHSPC) or non-metastatic castration-resistant prostate cancer (nmCRPC), Nubeqa is one of the most prescribed treatments.

I worked with an amazing team to update the Nubeqa iVA and HCP website to include the ARANOTE Study, which showed that Nubeqa in combination with chemotherapy significantly extended overall survival.

This led to Nubeqa being the only androgen receptor inhibitor (ARI) approved by the FDA to treat both mHSPC and nmCRPC in combination with docetaxel.